Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 526 | 50370-12-2 |
Dose | Unit | Route |
---|---|---|
2 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 14.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 93 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 78.62 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 95 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 17, 1978 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 406.20 | 23.76 | 69 | 1778 | 1900 | 50601377 |
Type IV hypersensitivity reaction | 253.80 | 23.76 | 48 | 1799 | 2434 | 50600843 |
Rash maculo-papular | 121.39 | 23.76 | 43 | 1804 | 26598 | 50576679 |
Oedema | 62.01 | 23.76 | 36 | 1811 | 70145 | 50533132 |
Drug hypersensitivity | 58.85 | 23.76 | 58 | 1789 | 250952 | 50352325 |
Veillonella infection | 27.87 | 23.76 | 4 | 1843 | 34 | 50603243 |
Cellulitis | 27.80 | 23.76 | 22 | 1825 | 70776 | 50532501 |
Neisseria infection | 27.38 | 23.76 | 4 | 1843 | 39 | 50603238 |
Drug reaction with eosinophilia and systemic symptoms | 26.16 | 23.76 | 15 | 1832 | 28409 | 50574868 |
Stomatococcal infection | 24.38 | 23.76 | 4 | 1843 | 87 | 50603190 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 183.14 | 27.61 | 30 | 563 | 1232 | 29572702 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cross sensitivity reaction | 572.96 | 23.57 | 99 | 2092 | 3268 | 64493273 |
Type IV hypersensitivity reaction | 266.11 | 23.57 | 52 | 2139 | 3370 | 64493171 |
Rash maculo-papular | 103.91 | 23.57 | 44 | 2147 | 46982 | 64449559 |
Oedema | 65.44 | 23.57 | 40 | 2151 | 91895 | 64404646 |
Drug hypersensitivity | 45.98 | 23.57 | 48 | 2143 | 237767 | 64258774 |
Drug reaction with eosinophilia and systemic symptoms | 44.81 | 23.57 | 26 | 2165 | 54191 | 64442350 |
Toxic epidermal necrolysis | 36.60 | 23.57 | 20 | 2171 | 37146 | 64459395 |
Anaphylactic reaction | 32.07 | 23.57 | 23 | 2168 | 68641 | 64427900 |
Veillonella infection | 27.40 | 23.57 | 4 | 2187 | 42 | 64496499 |
Neisseria infection | 25.83 | 23.57 | 4 | 2187 | 64 | 64496477 |
Erythema | 24.62 | 23.57 | 31 | 2160 | 187039 | 64309502 |
None
Source | Code | Description |
---|---|---|
ATC | J01DB05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Streptococcal tonsillitis | indication | 41582007 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Tonsillitis | indication | 90176007 | DOID:10456 |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Prevention of Bacterial Endocarditis | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Species | Use | Relation |
---|---|---|
Cats | Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus | Indication |
Cats | Genitourinary tract infections caused by Escherichia coli | Indication |
Cats | Genitourinary tract infections caused by Proteus species | Indication |
Cats | Genitourinary tract infections caused by Staphylococcus aureus | Indication |
Cats | Skin and soft tissue infections caused by Pasteurella multocida | Indication |
Cats | Skin and soft tissue infections caused by Staphylococcus epidermidis | Indication |
Cats | Skin and soft tissue infections caused by Streptococcus species | Indication |
Dogs | Skin and soft tissue infections caused by Staphylococcus aureus | Indication |
Dogs | Genitourinary tract infections caused by Escherichia coli | Indication |
Dogs | Genitourinary tract infections caused by Proteus species | Indication |
Dogs | Genitourinary tract infections caused by Staphylococcus aureus | Indication |
Product | Applicant | Ingredients |
---|---|---|
Cefa-Tabs | HQ Specialty Pharma Corp. | 1 |
Cefa-Drops | HQ Specialty Pharma Corp. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.77 | acidic |
pKa2 | 9.72 | acidic |
pKa3 | 13.53 | acidic |
pKa4 | 7.63 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 15 member 1 | Transporter | Ki | 2.14 | WOMBAT-PK | |||||
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
ID | Source |
---|---|
4018151 | VUID |
N0000146488 | NUI |
D00257 | KEGG_DRUG |
119922-85-9 | SECONDARY_CAS_RN |
1297878 | RXNORM |
4018151 | VANDF |
C0007538 | UMLSCUI |
CHEBI:53667 | CHEBI |
CHEMBL1644 | ChEMBL_ID |
DB01140 | DRUGBANK_ID |
D002434 | MESH_DESCRIPTOR_UI |
47965 | PUBCHEM_CID |
4831 | IUPHAR_LIGAND_ID |
280111G160 | UNII |
d00080 | MMSL |
004959 | NDDF |
13414000 | SNOMEDCT_US |
372651006 | SNOMEDCT_US |
66592-87-8 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3196 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3196 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4059 | TABLET | 1000 mg | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9766 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9767 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9947 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9948 | TABLET, FILM COATED | 1 g | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-135 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
CEFADROXIL | Human Prescription Drug Label | 1 | 16590-043 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-388 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-389 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-390 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-427 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-018 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-146 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
CEFADROXIL | Human Prescription Drug Label | 1 | 42549-504 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-503 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0580 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 50090-1915 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-428 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-2290 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3742 | CAPSULE | 500 mg | ORAL | ANDA | 13 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5693 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 14 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5694 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 14 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-589 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-589 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 57237-096 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |